Kura Oncology's Darlifarnib-Cabozantinib Combo Shows Strong Early Efficacy in Kidney Cancer
Event summary
- Kura Oncology reported Phase 1a trial results showing 33-50% response rates and median PFS of 13 months for darlifarnib plus cabozantinib in advanced ccRCC patients.
- The combination demonstrated durable clinical benefit with over half of patients remaining on treatment at data cutoff.
- Safety profile was manageable and consistent with individual agent profiles, with neutropenia successfully managed through dose adjustments.
- Global Phase 1b randomized study is underway to establish recommended Phase 3 dose for potential registrational study in 2028.
The big picture
Kura Oncology's positive early results for darlifarnib in combination with cabozantinib come at a time when kidney cancer treatment options are expanding beyond traditional immunotherapy and VEGFR-targeted therapies. The company is positioning itself as a potential disruptor in the RCC space by enhancing existing treatments through precision medicine approaches. Success here could validate Kura's pipeline strategy of combining targeted therapies to address high-need oncology indications.
What we're watching
- Clinical Validation
- Whether the durable response rates and manageable safety profile will translate into successful Phase 1b results and ultimately support regulatory approval.
- Competitive Positioning
- How this combination therapy positions Kura against existing TKI and HIF-2α monotherapies in the second- and third-line RCC treatment landscape.
- Development Timeline
- The pace at which Kura can advance from Phase 1b to a planned registrational study by 2028, considering ongoing enrollment challenges or data readouts.